

2016/17

ANNUAL REPORT



GALLIPOLI
MEDICAL RESEARCH FOUNDATION

Remembrance through research

Contents

- 3 Message from the Chairman Liam Kelly
- 4 Message from the CEO Miriam Dwyer
- 5 Message from the Director of Research Prof Darrell Crawford
- 6 GMRF Profile
- 7 The GPH Cancer Wellness Program
- 8 The GP Education Program
- 9 Research Highlights
- 10 Research Activities
- 17 GMRF PhD Scholarship Program
- 22 GMRF Innovation Grants
- 23 Board of Directors
- 30 Committees
- 32 Acknowledgements
- 33 Financial Highlights 2016–2017
- 34 Appendix – Publications
- 40 How you can help



Remembrance through research

Message from the Chairman Liam Kelly

Having served on the GMRF Board of Directors since 2015, it was an honour to be appointed chairperson last year. It has been exciting to work with a dynamic Board of Directors and to work more closely with an excellent Executive team.

I extend my sincere thanks to the former chairperson, Mr Tom Ryan for his tremendous contribution to GMRF and for his support. As a member of the Board of Directors since the establishment of GMRF in 2005 and chair since 2011, Tom has been integral to the growth of the Foundation. I am delighted that Tom remains on the Board.

GMRF has always had a strong focus on innovation and translation, and this has been very evident in the last year. I have full confidence in CEO Ms Miriam Dwyer and her team's ability to deliver on GMRF's mission of enhancing the health of our veterans and the wider Australian community.

The Foundation is well-placed to deliver immediate positive outcomes and also to make a significant longer-term contribution to the development of treatments and programs to enhance the health and wellbeing of veterans, their families and the community. These outcomes include:

- The GMRF Innovation Grants which enable dedicated staff at Greenslopes Private Hospital (GPH) to use their knowledge and experience to improve clinical outcomes.
- Equipping GPs with information and research outcomes to manage post traumatic stress disorder (PTSD) in their patients

through the GP Education Program; and online and peer-to-peer training module.

- The GPH Cancer Wellness Program which provides cancer patients at GPH and their families with support and advice.
- The PhD Scholarship program which funds the development of students and early career researchers.
- Clinical Trials providing patients access to potentially life-changing new treatments and advancing research into new treatments.
- A range of research projects covering the areas, in addition to PTSD, of liver disease, liver transplant, cancer, respiratory illnesses and ophthalmology.

That is just a snapshot of what the generous donors and corporate partners of GMRF have contributed to over the past 12 months.

I hope this Annual Report gives you a sense of what your support is helping to achieve. With your continued partnership we at GMRF will press on in our commitment to our veterans and to life-changing medical research.

Thank you.



Liam Kelly - Chairperson



“The Foundation is well-placed to deliver immediate positive outcomes and make a significant longer-term contribution...”

”

Message from the CEO Miriam Dwyer

We're not afraid to aim high here at the Gallipoli Medical Research Foundation. Our projects and programs have been established with a focus on high-impact outcomes for our community. The treatment options currently being developed in our laboratory are for serious illnesses that are having a devastating impact on thousands of lives.

The urgent need for this research is clear. Liver cancer stands as the fastest increasing cause of cancer mortality in the country, with a mortality rate of over 85% within five years of diagnosis. There is only one treatment option available for cancer patients at the moment, a chemotherapy based treatment with limited success. But like I've said above, we're not afraid to aim high, and we're not daunted by the enormity of this challenge.

Our Liver Cancer Unit has several research projects underway, as you'll read more about in the following pages of this report. I am confident in the team we have assembled, and by the strength of our community of supporters.

It is this community that drives our research. I am delighted when I, or one of my team, has the opportunity to directly engage with the community through conferences, public talks, and community presentations. The more we can spread the word on these important health issues, the closer we can get to developing solutions together.

In the past 12 months, we've received overwhelming support from local community groups and passionate individuals. Fundraising has included everything from gala dinners, golf days,

bake-sales, raffles, open gardens, and even a wonderful Christmas Carol spectacle in December 2016.

We are so grateful for this support and what it means to the progress of the research outlined in this report. Of particular note is the completion and publication of our PTSD Initiative. The Vietnam Veteran study which began in 2013 revealed a number of physical co-morbidities associated with posttraumatic stress disorder. Armed with this evidence, published in the Medical Journal of Australia, we got straight to work with RSL Queensland to translate this research into enhancing the health of our veterans now.

The GP Education Program (which you can read about on page 8 of this report) uses this world-first research as the basis of training material to equip GPs to better manage the signs and symptoms of PTSD. It saddens me to think of the veterans, particularly those of the Vietnam War, who received no recognition or treatment for the psychological toll of the service. The GP Education Program will ensure we can do better for our veterans, and help ensure they get the support they need and deserve.



Miriam Dwyer – Chief Executive Officer



“Our projects and programs have been established with a focus on high-impact outcomes for our community.”

Message from the Director of Research

Prof Darrell Crawford

The last 12 months have also been an exciting time of growth for GMRF; expanding our teams and pursuing new areas of research.

Our focus remains, as it always will, on innovative and translational research. The work that has taken place in our institute over the past 12 months will inform the development of treatments into serious illnesses such as fatty liver disease and liver cancer.

Our Liver Cancer Unit is the only dedicated liver cancer research facility in Queensland. This unit currently has a number of research projects all with a unifying goal; to develop new treatment options that will change liver cancer from a death sentence into a treatable chronic illness within our lifetime. It's incredibly innovative work - but it requires a lot of time and money.

Exploring and testing new treatments is not a quick process, but committing to this work now could save countless lives in the future. Our Liver Cancer Unit

Another significant achievement from the 2016/2017 year is the progress of the students in our PhD scholarship program. We have two students who are in the process of completing their PhD and another four who have recently joined us across the areas of liver disease, liver transplant, and ophthalmology.

It is very exciting for me to witness these brilliant and committed students at work, and I am honoured that GMRF can have a hand in the development of their research careers.


As has always been the case, it is our generous donors who have played crucial role in the progress we have made these past 12 months. Our PhD Student Program is generously funded by our Discovery Partners. With generous donors funding students and early-career researchers, I am extremely confident that we are on track in our mission to enhance the health of our veterans and the wider Australian community.

As we move forward, our vision remains clear: to enhance the health of the Australian community through the highest quality medical research. This is not science for science sake. Rather, we want to develop real-world, clinically relevant solutions which can treat – and even cure – disease.

Thanks again.



Darrell Crawford – Director of Research



“

The work that has taken place in our laboratory over the past 12 months will inform the development of treatments into serious illnesses such as fatty liver disease and liver cancer.

”

GMRF Profile

About us

Gallipoli Medical Research Foundation is an Approved Research Institute (ARI) committed to life-changing medical research.

We engage with individuals, businesses, and communities to grow the research of the Gallipoli Medical Research Institute. We focus on translational research with immediate and meaningful impact. We are proud to be based on the campus of Greenslopes Private Hospital (GPH).

The in-kind support we receive from GPH, in combination with the income we derive from our

Clinical Trials Unit, pays for our administrative costs.

Therefore, 100% of donations we receive go directly to medical research.

Our vision

Enhanced health of the Australian community through the highest quality medical research.

Our mission

To lessen the impact of serious illness today while also searching for the cures of tomorrow by:

- Working to alleviate the burden of disease

impacting our Veteran community

- Providing the infrastructure, governance and resources to support approved research endeavours
- Conducting and funding translational laboratory research; research that can have the quickest movement from 'bench to bedside'



GPH Cancer Wellness Program



Cancer patients practice mindful walking during a GPH Cancer Wellness Program seminar.



Ranee presents a patient with a Kimmie doll, an emotional support tool for patients undergoing chemotherapy.



Cancer patients at a wellness program seminar are taught a range of stretching and mobility exercises.

The Gallipoli Medical Research Foundation is committed to alleviating the burden of serious illness, not only through the development of new treatment options for future generations, but through practical support for people suffering from illness right now. The GPH Cancer Wellness Program, funded by GMRF donors, commenced this year and is providing cancer patients and their families with practical information, advice and support.

Program Coordinator Update - Ranee Saffioti

Since commencing as the Cancer Wellness Program Coordinator earlier this year, I'm thrilled to report that we have reached over 75 patients, their carers and support network. This program complements the hospital's existing oncology inpatient and day patient units, with a holistic approach to cancer care.

So far, we have conducted monthly education sessions which provide patients and their carers with practical tools and emotional support to assist in managing cancer treatment and mental wellbeing. Patients now also receive a discharge pack upon completing treatment, which supports survivorship and assists with the transition back to daily life post treatment.

We have facilitated a Survivorship Workshop, the first of what is hopefully a regular session, for patients who've completed treatment. Following this, our patients now receive a follow up phone call after they have completed treatment.

I've been extremely blessed to be able to coordinate the program. It is especially heart-warming to witness patients who were struggling and feeling lost become empowered to better manage their treatment.

Thank you so much to the generous Gallipoli Medical Research Foundation donors who make this all possible. You are the reason we have been able to create this program and provide a holistic approach to cancer wellness.



It is especially heart-warming to witness patients who were struggling and feeling lost become empowered to better manage their treatment.



GP Education Program




Based on the finds of the **PTSD Initiative**
Research to restore lives



GMRF and RSL Queensland launch the PTSD Initiative results to the public in April 2017.



GP Education Ambassador Dr Phil Parker explains to GPs the research and what it means for treating patients with PTSD.



GMRF staff attend national conferences for GPs to spread the word on our GP Education Program.

The GP Education Program is based on the findings from GMRF's PTSD Initiative, a world-first study examining the long-term physical impact of posttraumatic stress disorder on Australian Vietnam veterans.

This program will better equip doctors and other healthcare professionals to identify the physical signs and symptoms of PTSD. The GP education program will include three components; expert videos, an online education module and a GPCE program (national conference program).

To date, 554 health professionals have enrolled in our online education module, with 442 completions. Of those, 94% stated they would be confident managing a patient with PTSD having completed the education.

We have now delivered the education to 270 GPs face-to-face as part of our national PTSD roadshow and have further presentations planned for GP conference in Melbourne in November. This is in addition to the GPs who have completed the PTSD education online. We look forward to providing you with further updates soon as this translational program continues.

GPCE Conference Feedback:

"An excellent presentation on a very important issue – I have managed Vietnam Veterans over the years but this certainly brings all the information together. The knowledge gained from this activity will definitely improve my engagement with the families I work with."

The aim of the GP Education Program is to increase awareness. Training in the treatment of PTSD has not been adequately addressed for general practitioners and patients often won't divulge experience of PTSD because they don't feel like it's relevant.

Dr Phil Parker - GP Education Program Ambassador

Research Highlights 2016/2017

Cancer Research

In the past 12 months, our Liver Cancer Unit has established foundations for preclinical testing of new liver cancer therapies. Highlights:

- Developing a novel viral construct designed to infect cancer while sparing healthy cells.
- Evaluating the characteristics of liver cancer stem cells and identifying ways to target these cells directly.
- Screening liver cancers for signatures which enable the cancer cell to spread throughout the body and assessing agents which inhibit or reverse this process.



Discovering
new ways to
target cancer
stem cells

Liver Disease Research

With your help, our Liver Research Unit has been working to improve liver health. Highlights:

- Continuing research into liver transplant outcomes. We're aiming to improve the quality of donor livers to help address the shortage of suitable organs and reduce the number of livers that fail after transplant.
- Continuing research into fatty liver disease. The focus has been on examining molecules released by fat cells which may play a role in liver disease progression.

Progressing
research to help the
1 in 4
Australians with
fatty liver

Veteran Mental Health

Our Veteran Mental Health team has been putting world-first research into clinical practice. Highlights:

- Published our PTSD Initiative Vietnam veteran study which identified a number of physical co-morbidities associated with post-traumatic stress disorder.
- Rolled out a national education program to help GPs identify and treat the signs and symptoms of PTSD.
- Completed Phase I of the study to understand the transition from service to civilian life. By better understanding the cultural reintegration and psychological adjustment process the team aim to enable more effective assessment and intervention to address transition difficulties.

500
GPs enrolled /
completed online
education.

Ophthalmology

The Ophthalmology Unit introduced new research focuses in therapeutic development for ocular disease and blindness. Highlights:

- Established new local collaborations to progress current research targets into new therapies.

WORLD FIRST
The team engineered
intraocular gene therapy
to pass through the
outer blood retina
barrier

- Established a ground-breaking human retinal explant model of eye disease in collaboration with the Queensland Eye Bank, enabling investigation of disease and therapeutics in tissues without animal experimentation.

Respiratory

Our Respiratory Research Unit has taken major steps forward in laboratory research and clinical trial treatments for lung infections. Highlights:

- Established a mycobacteriology facility at GMRF which will further the drug development pathway to enhance treatment options for patients.
- Started recruitment for a macrolide resistance study which will guide future policy regarding long term antibiotic use in Bronchiectasis
- Exploring the immune responses to bacteria in chronic lung disease, to open new avenues for host directed treatment.

8 Journal
publications
in 2016/2017,
contributing to global
understanding of lung
infections

Research Activities 2016/2017

Liver Research Unit led by Professor Darrell Crawford

100% of required funding for the Liver Research Unit during the 16/2017 Financial Year was provided by GMRF donors

One PHD awarded.
TWO NEW STUDENTS JOINED THE LIVER RESEARCH UNIT IN THE PAST 12 MONTHS

9 New publications contributing to the global knowledge on liver disease

In the past twelve months the GMRF Liver Research Unit has been focusing on two major research themes:

The first examines the outcome of liver transplants and how we can improve the quality of donor livers. There is a shortage of donor organs in Australia, with many livers deemed unsuitable for transplant.

We hope our studies will enable us to determine which donor livers are likely to be successfully transplanted and those which may fail. This would ensure better outcomes for patients undergoing liver transplantation. In addition we hope to target injury pathways with drugs that can block these pathways, thus reducing the development of injury in transplanted liver.

The second theme focuses on fatty liver disease and to determine if excess iron in fat tissue plays a role in worsening the injury in the liver. Fatty liver disease affects 1 in 4 adults and its prevalence is increasing due to the obesity epidemic. Our studies aim to examine pathways

linking liver injury and adipose tissue (fat tissue).

While the initial experiments are all using cell and animal models we hope to identify and understand pathways that will lead to future studies in humans – such as treatments for fatty liver.

Over the course of the past 12 months, members of the Liver Research Unit have presented at

- Australian Gastroenterology Week
- Annual Scientific Meeting, The Transplant Society of Australia and New Zealand
- GE Society of Queensland (GESQ)
- Asian Pacific Association for Study of the Liver

The Liver Research Unit currently have five NHMRC grants pending, with outcomes to be announced in 2018.

Dr Janske Reiling received her joint PhD from both The

University of Queensland and Maastricht University. Dr Reiling was also a finalist in The Australian Gastroenterology Week Young Investigator Awards.

The Liver Research Unit continued to build strong research partnerships to produce effective collaboration in innovative research into various forms of liver disease.

INTERNATIONAL:

A/Prof Ari Cohen, Ochsner Medical School, New Orleans
Professor C. Dejong, University of Maastricht, The Netherlands

NATIONAL:

Professor Leon Adams, University of Western Australia

LOCAL:

Professor Michael Roberts, Uni SA and TRI
Professor Grant Ramm, QIMRB

Research Activities 2016/2017 continued

Liver Cancer Unit led by Dr Jason Steel

GMRF

operates the only dedicated liver cancer unit in Queensland

EXPANSION OF THE LIVER CANCER UNIT

with the addition of a new PhD Student.

7 publications in international journals

Over the past 12 months our research team has focused on setting the foundation for preclinical testing of targeted therapies for liver cancer. We have 3 main streams of research with interlinking aims based on the theme of targeting the cancer while sparing the liver.

The first stream involves the generation of novel viral constructs which have been designed to specifically infect and express a therapeutic gene in the cancer while sparing normal cells. This work is ambitious and innovative. The outcome, if successful, would be a new class of targeted treatment for liver cancer, with the potential to be used in other cancer types.

The work is being led out of the GMRI by Dr Steel with collaborators in CMRI (Sydney) and NIH (USA). It is long term project with measurable outcomes at each stage of the treatment's development.

The second stream involves the targeting of cancer stem cells. The cancer stem cell is responsible for tumour

initiation, maintenance, and progression.

Over the past 12 months we have been evaluating the characteristics of liver cancer derived cancer stem cells. We have been identifying targets on these cells for possible treatment and have been evaluating whether the cancer stem cell signature can be used to identify patients that have worse prognosis.

The work is being led out of the GMRI by Dr Steel with collaborators in University Cincinnati (USA), US Naval Medical Research Center (USA), Ochsner (USA) and Griffith University. The work is moving towards preclinical evaluation of a vaccine targeting the cancer stem cell, which will be starting this year.

The third stream involves targeting the metastatic pathway. This work has involved screening the liver cancers for signatures consistent with a mesenchymal characteristic which enable the cancer cell to move and to assess agents that may inhibit or reverse this process, thereby preventing the tumour from metastasising.

Over the past 12 months we have been assessing the cancers for these characteristics and have started to evaluate drugs for their ability to reverse this process. This work is also led out of GMRI by Drs Steel and Jayachandran with collaborators from QUT.

The Liver Cancer Unit has continued to contribute to global knowledge on liver cancer through presentations and posters at seven conferences and eight publications in international journals.

"Our research focuses on targeted treatments with the goal of killing the tumour cells while largely sparing the remaining cells of the liver. This specific targeting of the cancer is vital to improving clinical outcomes for this disease."

Dr Jason Steel

Research Activities 2016/2017 continued

PTSD Initiative led by Dr Sarah McLeay

GMRF PTSD INITIATIVE

VIETNAM VETERAN STUDY published in the Medical Journal of Australia

The main focus of the PTSD initiative team throughout 2016/2017 has been completing sleep sub-studies and disseminating results. Study recruitment for the PTSD-03 actigraphy and PTSD-07 polysomnography studies has been completed.

The main results from the PTSD-01 study were published in the Medical Journal of Australia and other results were presented at eight national and international conferences throughout the year.

Two publications describing genetic results and a publication on cardiac disease have been published in peer-reviewed journals in the past 12 months. Writing and submitting of a further nine manuscripts is currently underway, including from the PTSD-03 and PTSD-07 sub-studies.

Collaborations have also been formed and developed based out of Harvard University in the USA during the past 12 months. De-identified data have been shared with the PTSD Psychiatric Genetics Consortium, allowing results from the PTSD study to be part of international investigations into the genetics of PTSD.

Presentation of abstracts at **SIX** major conferences

As part of the PGC, the PTSD Initiative team will inform analysis and future projects. Additionally, collaboration was initiated with a dietician Dr Ingrid Hickman and student from the Princess Alexandra Hospital to analyse dietary intake data from the PTSD-01 study.

A systematic review pertaining to dietary intake and PTSD-related cardiometabolic disease was prepared and submitted for publication. With the expertise of a dietician, informed analysis of the PTSD-01 dietary intake data is underway.

With the publication of the main results from the PTSD-01 study, the results have been widely disseminated. The media release, discussion panel, and ABC interview with Professor Darryl Crawford have allowed results to be shared with the community as well as academic peers.

The results from the PTSD-01 study have generated clinical impact through the GP education initiative. Over 400 GPs have completed a PTSD educational module directly informed from the PTSD-01 study. (See page eight of this report for more information on the



RESEARCH IMPROVING EDUCATION

Launching of a nation-wide GP Education program to improve management of PTSD.

GP Education Program).

The PTSD-01 study is also informing future research with implications for veteran and PTSD-related health including sleep, gut health, liver function, and respiratory health.

The PTSD Initiative is funded by the generous support of RSL Queensland.



RETURNED & SERVICES
LEAGUE OF AUSTRALIA
QUEENSLAND BRANCH

Research Activities 2016/2017 continued

Veteran Mental Health Initiative led by Dr Madeline Romaniuk

COMPLETION

of Phase I of the VMH Initiative

Service to Civilian

NINE presentations
at academic
conferences and
community forums

Analysis of 2198 pages
of audio recording transcripts from
study participant interviews

The purpose of the Veteran Mental Health Initiative (VMHI) is to build a strong foundation of mental health research among the contemporary veteran cohort which will generate evidence to guide developments in procedures and practices to improve the well-being of the veteran community. Over the past 12 months, the VMHI team has focussed on the following projects:

Veteran Reintegration Study

Understanding the issues surrounding transition and reintegration, and developing support tools.

All 100 interviews were completed by December 2016. The qualitative data resulting from the interviews included 2198 pages of transcripts of audio recordings. This data is currently being analysed and has informed the development of stage 2 of the study. Early findings of stage 1 were presented by Dr Romaniuk at the PTSD17 Forum hosted by StandTall for PTS and at the Canadian Institute of Veteran & Military Medicine Forum in Toronto. The protocol for stage 2 of the research is currently under review by the ADF/DVA ethics committee.

Post War: Survive to Thrive Program Evaluation

Evaluation of the effectiveness of an online program to contribute to the limited research examining online interventions for veteran populations.

Twenty-nine former ADF members participated in the online program and completed a battery of self-report measures. Following data analysis, a comprehensive report was written by the VMHI team and presented at PTSD17 and the Australasian Military Medicine Association Conference (AMMA).

Equine Therapy Program

Evaluation of the Mates4Mates Equine Therapy Program.

Data collection commenced in mid 2016. Eleven equine assisted therapy programs were run in 2016 with a total of 66 current and former Australian Defence Force members and spouses participating in both Individual and Couples programs. Dr Romaniuk presented results at the Canadian Institute for Military and Veteran Health Research Forum, in Toronto.

SIMPAQ Study

Validation of the Simple Physical Activity Questionnaire (SIMPAQ) to ensure the accurate assessment of physical activity among those with mental illness.

Recruitment of 1060 participants for the SIMPAQ validation study was completed in July 2017 which included 43 sites in 24 countries. Twenty participants completed the study from GMRF between October 2016 and July 2017 with VMHI staff completing data collection for this cohort. Participants included veterans with PTSD, and staff at the Keith Payne Unit at Greenslopes Private Hospital assisted with recruitment. Data analysis is currently underway by the lead investigators at UNSW.

The Veteran Mental Health Initiative is funded by the generous support of RSL Queensland.



Research Activities 2016/2017 continued

Ophthalmology Research Unit led by Associate Professor Chris Layton

WORLD-FIRST

Engineered intraocular gene therapy to pass through the outer blood retina barrier



Awarded 'BEST POSTER'

at the 2016 European Association for Vision and Eye Research Conference

8

publications in
peer-reviewed
journals

Over the past 12 months, the Ophthalmology Research Unit has extended its focus on targeted retinal therapeutic development and delivery. They have established local collaborations to facilitate rapid transfer of our existing research targets to therapeutic solutions.

This has included modifying and selecting established vectors to allow tissue specific delivery without major surgery in the eye. Another focus has been on establishing a ground-breaking human retinal explant model of eye disease in collaboration with the Queensland Eye Bank. This has been developed to the point of allowing scientific investigation of disease and therapeutics in tissues which are arguably more valid than established animal models of eye disease.

In a world first, the team has engineered intraocular gene therapy to pass through the outer blood retina barrier to target choroidal diseases like macular degeneration and choroidal melanoma, and our clinical projects continue to show remarkable success, including the development of a 100% sensitive test

for spontaneous retinal vein pulsation in patients with normal intracranial pressure.

The Ophthalmology Research Unit has taken on three new full-time scientific members over the last 12 months. The focus has been on introducing them to the new area of ophthalmic science and applying their existing skills to the problems of ocular disease and blindness.

Major partnerships during the past 12 months include;

International:

- Neville Osborne (Oxford University)
- Anthony Bron (Oxford University)

National:

- Robert Casson and John Wood (Hanson Institute, Adelaide)
- Leszek Lisowski (Children's Medical Research Institute)

Local:

- Katie Edwards (QUT)
- Beatrix Feigl (QUT/IHBI)
- Andrew Zeil (QUT/IHBI)
- Nigel Barnett (UQCCR)
- Queensland Eye Bank
- LANDMARK Biobank
- Dr Jasonal Steel (UQ)

"This research represents the next generation of targeted therapeutics to prevent or treat blinding or fatal eye diseases such as diabetic retinopathy, macular degeneration and choroidal melanoma with "one and done" therapeutic designs."

Associate Professor Chris Layton

Research Activities 2016/2017 continued

Respiratory Research Unit led by Associate Professor Rachel Thomson

Establishment of a mycobacteriology facility at GMRF

TWO STUDENTS
completed a **RESEARCH DEGREE AWARD**
with the GMRF Respiratory Research Unit

8 Journal
publications in the
past 12 months

Over the past 12 months there have been a number of key focus areas and milestones achieved by GMRF's Respiratory Research Unit, led by Dr Rachel Thomson.

Of particular significance is the establishment of a mycobacteriology facility within the GMRF laboratory. The establishment of this facility will enhance the team's ability to perform work, such as antimicrobial susceptibility testing of new compounds against nontuberculous mycobacteria (NTM). This will further the drug development pathway that will enhance treatment options for patients. The lab will also be used for further testing of environmental samples to increase our understanding of the pathogenesis of disease. This will improve patients ability to minimise exposure to NTM following successful treatment.

The team has also commenced 2 NHMRC projects including recruitment to the Macrolide resistance study. Results of the NHRMC Macrolide resistance study will guide future policy regarding long term antibiotic use in Bronchiectasis,

providing better outcomes for patients with this disease.

The findings of the National NTM in CF study will significantly inform epidemiology of NTM in Australia (clinical, environmental and microbial epidemiology) and transmission dynamics of this pathogen that has been shown to spread patient to patient and within hospital units. It will also form a platform for future treatment trials. Whole genome analysis of organisms obtained will allow development of new antibacterial targets, and better treatments.

Furthering our understanding of host susceptibility will allow development of targeted non-antibiotic therapies to enhance our ability to treat these recurring infections and maintain more long term remission from disease.

Assoc. Prof. Thomson expanded her consultancy work to enhance clinical trial activity in NTM and bronchiectasis through the Clinical Trials unit. Clinical trial activity will likely improve available

treatments for patients with NTM disease.

Epidemiological work has included the preparation of data for a large scale geospatial analysis of NTM in QLD. Further smaller analyses of the spectrum of disease caused by rarer species of NTM including *M. triplex* and *M. szulgai*.

The Respiratory Research Unit has also contributed to the establishment of Australian Bronchiectasis Registry, and linkages with European and US registries as platform for future research in Bronchiectasis.

Clinical Trials Unit

Leading the way in providing patients with access to new treatments

Over the past 12 months, the Gallipoli Medical Research Foundation Clinical Trials Unit (CTU) has remained committed to providing patients with access to life-changing new treatments.

Based at Greenslopes Private Hospital, the CTU is currently conducting a range of trials across oncology, liver disease and respiratory illnesses.

In August, the CTU team was recognised by the Association of Regulatory and Clinical Scientists (ARCS) Australia. The GMRF Clinical Trials Unit received the ARCS Favourite Investigational Site 2017 Awards, as voted by industry peers and sponsors.

"I am very proud to have our unit recognised for the conduct of clinical trials, conducted in collaboration with clinicians from Greenslopes Private Hospital. This award gives sponsors the confidence that trials conducted at GMRF will be efficiently and professionally managed," GMRF Clinical Trial Manager Suzanne Elliott says.

New medicines can only be registered for use on the basis of evidenced-based clinical trials. The CTU currently has about 40 clinical

trials open, with three-quarters of these either recruiting, dosing or in participant follow up.

There are 16 melanoma trials conducted by our Clinical Trials Unit currently in dosing or patient follow-up and 7 new oncology trials commenced in the past 12 months.

For more information or to view current trials, visit
www.gallipoliresearch.com.au/site/CLINICAL-TRIALS

"We really enjoy working in the Australian trial environment to progress new drug development to make these available for our patients," Dr Suzanne Elliott



HEP C Trials achieve 81% cure rate

Over the course of nine years, GMRF participated in 28 Hep C Trials involving a total of 169 Patients.



GMRF PhD Scholarship Program



PhD research: Targeted Adeno associated viruses for Hepatocellular Carcinoma

Student: Mr Bijay Dhungel

Supervisors: Dr Jason Steel

Over the past 12 months, Mr Dhungel has developed a protocol to manufacture viral vectors in large quantities. The aim is to use viral vectors to target the cancer cells directly, rather than also attacking healthy cells.

He has tested his viral vectors in cell lines and major organs of the body. Following this, Mr Dhungel plans to progress this research to preclinical testing.

Mr Bijay Dhungel has successfully completed the mid-candidature review milestone as per the requirement of the University of the Queensland.

Mr Dhungel has had a busy year consolidating and presenting his research findings. In addition to a number of poster presentations at national and international conferences about his research, Mr Dhungel has published the introduction of his thesis as a review article and has submitted the second chapter (currently under review).

The chapters and the layout for the PhD thesis have been decided and the experiments required for its completion has been planned.

As part of his research, a working protocol for the construction and titration (quantification) of the viral vectors has been established

and the panel of cell lines required to check for the hepatocellular carcinoma (HCC) specificity of the vectors has been increased to cover most of the important organs.

He has tested two of the modified vectors in a few cell lines and preliminary studies show encouraging results.

He and the Liver Cancer Unit are in the process of manufacturing the vectors in large scale and testing them across the panel of cell lines they've collected. The selected viral vectors will then be tested in mice model of HCC.

As a side project, he is also working closely with the Ophthalmology group in developing AAVs best suited for ocular gene therapy.

Over the past 12 months, Bijay has contributed 13 publications, including 6 as lead-author.

"It's all about developing the technique. If it works for liver cancer it'll work for other types of cancer as well,"

Mr Bijay Dhungel.

Mr Bhungel's full PhD Scholarship is generously provided by the Thorsen Family Foundation.

GMRF PhD Scholarship Program continued



PhD research: The role of adipocyte iron in non-alcoholic fatty liver disease

Student: Dr Laurence Britton

Supervisors:

Professor Darrell Crawford, Dr Kim Bridle

Dr Laurence Britton is aiming to submit his PhD in the next few months. Four of the five proposed chapters have been submitted to peer-reviewed journals, two have been published and a further two are currently undergoing peer review.

This year has been focused on thesis writing and the completion of an adipocyte (fat) cell culture series of experiments in which the effect of iron on fat cells was studied in detail. This work will form the final chapter, which is currently being prepared for submission.

The key findings of Laurence's PhD are that:

1. In people with fatty liver disease, increasing liver iron appears to be associated with a lower degree of insulin resistance (pre-diabetes).
2. Iron blocks the secretion of Apolipoprotein E (ApoE) from human fat cells (adipocytes). As ApoE appears to protect against fatty liver disease, targeting adipocyte iron and ApoE may be future targets for the treatment of fatty liver disease.

Other Involvement:

- GE Society of Queensland (GESQ) organising committee member 2016-2017
- Senior Lecturer for Greenslopes Clinical School
- Student Representative, Research Higher Degree Committee, School of Medicine

Publications

Britton LJ, Subramaniam VN, Crawford DHG
Iron and non-alcoholic fatty liver disease, World J Gastroenterol.
22(36): 8112-22, Sep 2016

The incidence rate Non-alcoholic fatty liver disease is increasing rapidly in Australia, affecting almost one in three adults.

Fatty liver disease often presents no symptoms and can progress to liver failure, liver cancer, diabetes and heart disease.

“Around one billion people in the world have fatty liver disease. Fortunately, only a small proportion will go on to develop liver failure or liver cancer. The focus of our research is to find new ways to identify those most at risk and develop better treatments for them.”

Dr Laurence Britton

GMRF PhD Scholarship Program continued



PhD research: Genetic, biomarker and psychological factors for risk and resilience of PTSD

Student: Mrs Dagmar Bruenig

Supervisors: Dr Joanne Voisey, Prof R McD Young

Current serving Australian Defence Force members have a 3.9% rate of reported suicidal ideation over the past 12 months, more than double that of the general Australian population of 1.7%.

Research revealed genes involved in the vulnerability to PTSD that are in common with neurodegenerative disorders such as Alzheimer's disease.

Mrs Dagmar Bruenig successfully presented her final seminar in December of 2016. In February 2017 she submitted her thesis for external review and have received feedback from examiners with the recommendation of degree award after some modifications.

These modifications have been implemented and approval from the supervisory team has been obtained. The thesis is currently in submission with the Postdoctoral Research Coordinator of the School of Biomedical Sciences, QUT, for final approval. After this step, the thesis should be forwarded for conferral.

Two of Mrs Bruenig's publications from her PhD and another co-authored publication were accepted for publication in 2017. Another publication from the PhD and another co-authored publication are currently under review.

Oral presentation at the Australasian Conference on Traumatic Stress (ACOTS) at Gold coast (September 2016): "The role of NOS1AP and NOS1 in PTSD"

Poster presentation (October 2016) at The 4th Annual Molecular Psychiatry Meeting Maui, Hawaii, USA: The role of NOS1 and NOS1AP in PTSD, comorbidities and resilience

Published:

Mehta, D, Bruenig, D, Carrillo-Roa, T, Lawford, B, Harvey, W, Morris, CP, Smith, AK, Binder, EB, Young, RMD, Voisey, J (2017). Genomewide DNA methylation analysis in combat veterans reveals a novel locus for PTSD, *Acta Psychiatrica Scandinavica*, 2017, doi: 10.1111/acps.12778

Bruenig, D, Morris, CP, Mehta, D, Harvey, W, Lawford, B, Young, RMD, & Voisey, J (2017). Nitric oxide pathway genes (NOS1AP and NOS1) are involved in PTSD severity, depression, anxiety, stress and resilience. *Gene* 625, 42-48

Bruenig, D, Mehta, D, Morris Ch P, Harvey, W, Lawford, B, Young, R McD, Voisey, J (2017). Genetic and serum biomarker evidence for a relationship between TNFα and PTSD in Vietnam war combat veterans. *Comprehensive Psychiatry*, 74, pp. 125-133 (published online).

<http://dx.doi.org/10.1016/j.comppsy.2017.01.015>

Under review:

Bruenig, D, Mehta, D, Morris, Ph, Harvey, W, Lawford, B, Young, R, Voisey, J (under review). Correlations between

interferon γ and interleukin 6 with PTSD and resilience. *Psychiatry Research*

Mehta, D, Bruenig, D, Lawford, B, Harvey, W, Carrillo-Roa, T, Morris, Ph, Jovanovic, T, Young, R, Binder, E, Voisey, J (2017). Accelerated DNA methylation aging and increased resilience in veterans: the biological cost for soldiering on. *Translational Psychiatry*

Mrs Bruenig's work is made possible by the generous ongoing support of RSL Queensland.



RETURNED & SERVICES
LEAGUE OF AUSTRALIA
QUEENSLAND BRANCH

GMRF PhD Scholarship Program continued



PhD research: Aspects of posterior segment therapeutic targeting in retinal disease

Student: Slawomir Andrzejewski
Supervisors: Dr Chris Layton

Phd commenced in January 2017

Develop a gene therapy to treat various blinding conditions such as the Diabetic Retinopathy using the Adeno-Associated Viral (AAV) vector as the therapeutic agent.

Slawomir Andrzejewski is a 1st year PhD candidate at the University of Queensland. He obtained a Bachelor of Science Degree in Biomedical Science at Middlesex University in London, UK, where he devoted his dissertation project on cancer research. Later, he has been awarded the degree of Master of Science in Cell and Gene Therapy from University College London, UK. During his Masters project, together with researchers from the Institute of Ophthalmology he has worked on optimisation of adeno-associated viral vector for ocular congenital diseases.

Prior to joining the GMRF team, Slawomir also did a work placement at Adam Mickiewicz University, Poznan, Poland, where he researched target genes for muscular dystrophy. Now, thanks to Gallipoli Medical Research Foundation PhD scholarship and a UQ tuition scholarship, he had joined the Ophthalmology Research Unit where he combines his previously gained experience to apply a gene therapy for ocular diseases such as Diabetic Retinopathy and Uveal Melanoma.

Slawomir's PhD research project aims to develop a gene therapy to treat various blinding conditions such as the Diabetic Retinopathy using the Adeno-Associated Viral (AAV) vector as the therapeutic agent. The AAV vector will be equipped with various genes to improve the pathological environment in affected retinal tissue.

In the last six months, Mr Slawomir has completed construction of the bacterial plasmids which will be further used to make the AAV vectors. They have been tested showing that they are functional and can be used in further studies.

In the near future, Slawomir will perform a number of experiments to determine the therapeutic efficacy of his tested plasmids and vectors. Using retinal pigment epithelium (RPE) cells Slawomir has tested various AAV vector serotypes to define those which are transported across the RPE cells with higher efficiency, and which infect the RPE cells best.

Further studies are directed to use the designed plasmids containing the genes of interest to observe if they have a therapeutic effect.

The PhD scholarship is funded through the generous support of the Thorsen family Foundation

GMRF PhD Scholarship Program continued



PhD research: Aspects of diabetic retinopathy and diabetic retinal neuropathy

Student: Ms Aparna Murali

Supervisors: Dr Chris Layton

Phd commenced in the past 12 months

Develop a gene therapy to treat various blinding conditions such as the Diabetic Retinopathy using the Adeno-Associated Viral (AAV) vector as the therapeutic agent.

Aparna completed her Bachelor of Technology in Biotechnology and Master of Science in Genomics in India. She joined the Ophthalmology Research Unit in January 2017 for her PhD under the guidance of Dr Chris Layton. Her work focusses on diagnostic and therapeutic aspects of diabetic retinal neuropathy and diabetic retinopathy. She is currently developing primary human cell culture models for diabetic retinal neuropathy.

Donated cadaveric human eyes are viable for retinal research even after few days of death of a person when proper storage conditions are maintained. Photoreceptors are the most important cells for visual function and there are no reliable models to-date to study and experiment with photoreceptors in the human eye. We have established a consistent strategy to culture human retinal tissue explants, which and validated this by using it to perform experiments on human photoreceptors and other retinal neurons.

This is a significant breakthrough in studying human vision and related ocular diseases. This experimental model allows us to perform experiments with donated human eyes, reducing the need for animal experimentation and making the results of our scientific investigations more likely to be successful in translation.

Publications

A. MURALI, C. Ramlogan-Steel, S. Andrzejewski, B. Dhungel, J. Steel, C. Layton (2017) The 8-fold quadrant dissection method for ex vivo human interventional retinal experimentation *Acta Ophthalmologica* (in press) (Impact Factor 3.157)

GMRF Innovation Grants

For the past six years, the GMRF Innovation Grants, made possible by Hanrick Curran, have been contributing to practical advances in hospital operations and patient outcomes at Greenslopes Private Hospital.

Two grants projects were funded in the 2016 round of the GMRF Innovation Grants, both of which have made a measurable impact in improving clinical outcomes for staff and patients.



Project Title: A pilot study investigating the efficacy of Cognitive Processing Therapy (CPT) for the treatment of military-related PTSD in a Trauma Recovery Program (TRP)

\$15,000 was awarded to a group at the Keith Payne Unit to investigate whether Cognitive Processing Therapy (CPT) produces greater PTSD symptom reduction than treatment as usual in an accredited trauma recovery program.

The PTSD group program offered at KPU is specifically designed to assist both serving and ex-serving members of the Australian Defence Force (ADF), with a military-related posttraumatic stress disorder diagnosis. The multidisciplinary program has been running for 21 years and is funded by the Department of Veterans'

Affairs (DVA). While the program has maintained national accreditation status and continued to produce significant outcomes on the PTSD Checklist (PCL-5) and other participant feedback measures, the program has not enforced treatment guidelines for trauma-focused cognitive behavioural therapy (TF-CBT), in particular exposure therapy.

It is anticipated that the inclusion of Cognitive Processing Therapy will enhance clinical practice, program/ participant outcomes, and support ongoing quality improvement and accreditation requirements at GPH. As of midway through 2017, the group have incorporated Cognitive Processing Therapy into TRP for the first time. All Allied Health clinicians (7) completed online CPTWeb training, prior to commencement of study and 9 of 11 new TRP participants have consented to participate in 12 individual CPT sessions.

Project Title: Effects of post-operative analgesic technique on the rehabilitation outcomes for patients following a Total Knee Replacement (TKR)

\$8,000 was awarded to Senior Physiotherapist Pauline Teng to investigate the use of patches in the recovery process for patients who had received a total knee replacement. Immediately following the procedure, patients received two attachments; pain

relief in the form of a patient controlled analgesia (PCA) and an indwelling catheter. Because of these attachments, two staff members were required to assist with patient mobilisation, transfer, and assistance with hygiene care.

Early mobilisation is crucial to good recovery. Participation in exercise classes immediately following a total knee replacement has been shown to improve patient's mental and physical wellbeing. The use of a PCA attachment impedes on a patient's ability to join these classes until three or four days after surgery.

Pauline applied for a GMRF Innovation Grant so she could investigate whether the use of opioid analgesic patches compared to PCA will improve early mobilisation for patients and therefore lead to discharging from hospital sooner. By researching the impact of attachments, Pauline aims to shorten recovery time and improve overall patient wellbeing.

Norspan (Buprenorphine) and Fentanyl patches are both opioid analgesic patches used for post-operative pain management. Patients prescribed opioid analgesic patches do not therefore; have an IV line attachment post-operatively. Some orthopaedic surgeons at GPH use this as their preferred method of patient pain relief following TKR.



The 2016 GMRF Innovation Grants were funded by-

**Thynne
Macartney
Lawyers**

hanrickcurran
ACCOUNTANTS. STRATEGISTS.
Improvers. New Thinking.

Board of Directors

1 Dame Quentin Bryce (Patron)

AD CVO

Ms Quentin Bryce has enjoyed a rich and distinguished career as an academic, lawyer, community and human rights advocate, senior public officer, university college principal, and vice-regal representative in Queensland and for Australia.

Her contribution to advancing human rights and equality, the rights of women and children, and the welfare of the family was recognised in her appointment as an Officer of the Order of Australia in 1988 and a Companion of the Order of Australia in 2003. Also in 2003, she was invested as a Dame of Grace of the Most Venerable Order of the Hospital of St John of Jerusalem. On 5 September 2008 Quentin Bryce was sworn in as Australia's twenty-fifth Governor-General. Her term concluded in March 2014 and Prime Minister Tony Abbott announced on 25 March 2014 that Ms Bryce had become a Dame in the Order of Australia.

2 Mr Liam Kelly (Chairman)

BA (Hons) LLB (Hons) (UQ)

Liam Kelly graduated from the University of Queensland in 1988 with honours in English literature and in law. He was awarded the university medal for law. He was awarded the Rhodes Scholarship for Queensland in 1989 and attended Magdalen College at Oxford University from where he graduated in 1991 with a Bachelor of Civil Law. He commenced private practice as a barrister in Brisbane in 1992 and continues to practise at the bar as a Queen's Counsel. His field of work is commercial litigation.

3 Associate Professor David Colquhoun

MBBS, FRACP, FCSANZ

Associate Professor David Colquhoun is a Cardiologist in private practice. He has been extensively involved in research over the last 35 years involving multi-centre international trials and investigator initiated trials in the area of lipids, nutrition, nutraceuticals, diabetes and obesity. He has presented his research at national and international meetings. He has a private research organization (CORE Research).

He has published and been a referee for major journals. He has been the AMA spokesperson for Cardiology in Queensland. He is a member of the Scientific Committee of National Institute of Complementary Medicine. In 2008 he attended the 2020 Summit nominated by the National Heart Foundation. He was a member of the Queensland Government Smart State Council working group on prevention and early intervention approaches to tackle chronic disease.

He is Chair of the Prevention and Clinical Cardiology Council of the Cardiac Society of Australia and New Zealand. He was a member of the National Heart Foundation of Australia (NHFA) Nutrition and Metabolism Committee. He was Chief Author of the National Heart Foundation's position statement on fish and fish oil in 2008. He was Chair of the National Heart Foundation's Psychosocial Risk Factors and Coronary Heart Disease Expert Committee. He has been on the Board of the NHFA in Queensland since 2014. NHFA in Queensland since 2014.



1



2



3

Board of Directors continued

4 Mr Stephen Copplin FCPA, FAICD

Stephen is the Executive Chairman of the Marketing Director Centre Pty Ltd.

His professional career spans numerous industry sectors, including finance, insurance, investment banking, technology, media and creative industries. During his time, Stephen has successfully managed finance operations for multi-national corporations, negotiated multi-million dollar international acquisitions and divestments and built start-ups from inception through to trade sale.

Stephen is a Fellow Certified Practising Accountant, A Fellow of the Australian Institute of Company Directors and he has recently completed 15 years as an Adjunct Professor in the School of Business and the School of Electrical Engineering at the University of Queensland. As a professional Company Director, he currently holds a number of non-executive board positions with both public and private companies.

5 Adjunct Professor Tim Daniel

B.Bus, Grad Dip HR Mgmt., NZIoD

Following a career of more than 20 years in Medial sales, marketing and management (predominantly Orthopaedics) in New Zealand, Australia and the United Kingdom, Tim joined Ramsay Healthcare in February 2009 as the Chief Executive Officer (CEO) of Kareena Private Hospital, Sutherland Shire Sydney. Following a very successful restructure of clinical services and hospital developments, Tim was appointed to Ramsay's Westmead Private Hospital, Westmead Sydney in July 2011 again as CEO.

In December 2014, Tim was appointed as CEO of Ramsay's Greenslopes Private Hospital, Greenslopes Brisbane where he currently resides.

6 Professor Ken Donald AO

MBBS, PhD, FRCPA, FRCPath, FRACS(Hon), FRACMA

Originally trained as a Pathologist, Ken Donald has had appointments as an Academic Pathologist, Director of Pathology at Royal Brisbane Hospital and later at Hunter Area Pathology Services, and Professor of Anatomical Pathology at The University of Newcastle. Then followed post-doctoral studies at Erasmus University Rotterdam and Edinburgh University Scotland. He has also been Deputy Director-General of Health in Queensland (for a decade) and in the 1990's was Professor and Head of the Department of Social and Preventive Medicine at The University of Queensland and was, until the 31st December 2006, Head of the School of Medicine. He has chaired a number of major national authorities and committees within NHMRC, AIDS Control, Cancer Control and Veterans' Compensation Systems. In recent years he has been Director of Medical Services at Royal Darwin Hospital and Medical Assistant Commissioner on the Health Quality and Complaints Commission in Queensland, and recently retired as Chair of the Repatriation Medical Authority in the War Veterans Compensation System after nineteen years. He has published extensively in medical literature and Textbooks. In 2009/10 he was Director of Medical Services at Katherine Hospital, Northern Territory. He has recently been appointed Professor of Assessment and Evaluation at Griffith University Medical School. He has lead enquires for Queensland Health which involved post-graduate training, registration of overseas doctors and workforce supply and currently Cancer Services and Public Health Research. In 2007 he was made an officer of the Order of Australia (AO), and in June 2012 received the Premier's 2012 Queensland Great Award.



4



5



6

Board of Directors continued

7 Dr Michael Harrison

MBBS(1st Class Honours), FRCPA (General Pathology)

Dr Michael Harrison is the Chief Executive Officer/ Managing Partner of Sullivan Nicolaides Pathology and is a Consultant Pathologist at the main Taringa Laboratory. Dr Harrison graduated from the University of Queensland in 1977 with an MBBS (1st Class Honours) and in 1984 was awarded FRCPA (General Pathology).

Dr Harrison is the President of Royal College of Pathologists of Australasia and Chairman of the Quality Use of Pathology Committee. He has presented at many national and international meetings on the topics of Quality, Laboratory Management and e Health.

8 Professor Gerald Holtmann

MD, PhD, MBA, FRACP, FRCP

Professor Gerald Holtmann is a Clinical Academic with substantial leadership experience in the clinical and academic setting. He is Director of the Department Gastroenterology and Hepatology at the Princess Alexandra Hospital in Brisbane, and serves on the Board of Directors of the West Moreton Hospital and Health Service and is the Associate Dean Clinical at the University of Queensland.

He was born in Essen, Germany. He completed his clinical training in Internal Medicine and Gastroenterology at the University Hospital of Essen and by the age of 38, he was appointed Professor of Medicine there as well. He also completed a Fellowship at the Mayo Clinic, Rochester, Minnesota, USA. In 2004, he was appointed Director of Gastroenterology & Hepatology at the Royal Adelaide Hospital, and Professor of Medicine at the University of Adelaide. From 2007 to 2010, he served a term as Chief Executive Officer (CEO) and Medical Director of the University Hospital Essen. Professor Holtmann is a Fellow of the Royal College of Physicians in London and Fellow of the Royal Australasian College of Physicians.

His research is focused in the field of Neurogastroenterology and has continuously attracted peer reviewed funding from national and international funding bodies such as the National Health and Medical Research Council (NHMRC), and the German Research Foundation. He has published more than 350 articles and book chapters in leading journals including the NEJM, Lancet and Gastroenterology. Besides his clinical and academic activities, he completed a Master in Business Administration (MBA) at the University of South Australia.



7



8

Board of Directors continued

9 Ms Carmel Monaghan

B.BusComm, MBA

Ms Carmel Monaghan is Ramsay Health Care's Chief of Staff, following her appointment to this position in January 2015. In this role she is responsible for planning and directing the administrative, operational and strategic activities of the Office of the Chief Executive Officer. She is also responsible for the Company's global marketing strategy; brand management; public affairs; communications; and corporate social responsibility agenda.

Ms Monaghan joined Ramsay Health Care in 1998 and has directed the marketing strategy and communications of the Company through a time of several major mergers and acquisitions both within Australia and overseas, which has seen the Company grow from 12 facilities to over 200 and become one of the top five hospital operators in the world. During this time she has served in a variety of roles including most recently as Ramsay's Global Head of Marketing and Public Affairs since 2002, responsible for the coordination of the Company's marketing activities across the world and ensuring they aligned with improvement in business performance. Prior to joining Ramsay Health Care, Ms Monaghan was the Manager Public Relations and Media for the Queensland Branch of the Australian Medical Association (AMAQ) for four years between 1994 and 1998.

Ms Monaghan holds a Bachelor of Business (Communications) from Queensland University of Technology and completed a Master of Business Administration in 2002. In April 2016, Ms Monaghan was appointed as a Director of Générale de Santé, a publicly listed hospital operator in France in which Ramsay Health Care (UK) Limited has an interest.

She was a Board member of the Veterans' Research Foundation between 1998 and 2005 and is currently a Director and Company Secretary of the Gallipoli Medical Research Foundation, a role she has held since the Foundation's inception in 2005.

10 Mr Karl Morris

BCom, FAICD, MSAFAA, FFSIA

Karl Morris is Executive Chairman of Ord Minnett Limited with a career spanning over 30 years in financial services and wealth management. He is a Commerce graduate of Griffith University and holds diplomas from the Stockbrokers and Financial Advisers Association of Australia, Institute of Company Directors and FINSIA.

Karl is Chairman and a Master Member of the Stockbrokers and Financial Advisers Association of Australia, Chairman of QSuper, Director of the Royal Automobile Club of Queensland (RACQ), Director of Gallipoli Medical Research, Board Member of JP Morgan Australia Advisory Council, Board Member of the Financial Sector Advisory Council, Board Member of Archdiocese of Brisbane Catholic Foundation, Chair of Mary MacKillop Brisbane Catholic School Access Fund, Chair of Griffith University Foundation Board, Governor of the University of Notre Dame Australia and Patron of Bravehearts, a child protection charity.



Board of Directors continued

11 Professor John Pearn AO RDF MBBS
(Hons I), MD (Qld), PhD (Lond), DSc, MPhil, DCH,
FRACP, FRCP, FRCPS (Glas), FRACMA, FCollTropMed
(Australas), FCollTropMed (USA), FAMA, FADI, FAIM, FLS

Major General John Pearn has served as one of Australia's most senior doctor-soldiers. As Professor Pearn, he is a Senior Paediatrician at the Lady Cilento Children's Hospital in Brisbane; where, at its predecessor the Royal Children's Hospital, he has been a full-time staff clinician since 1968. His major clinical, research and teaching interests in paediatrics and internal medicine have included medical genetics, clinical toxicology, bioethics and accident prevention. Major General John Pearn also served in a second career in the Australian Defence Force, rising progressively through various senior command and executive positions in the Defence Health Service prior to being promoted to the rank of Major General. In 1998 he was appointed Surgeon General to the Australian Defence Force. He served in this role until his retirement in 2000. He is the National Patron of the Peacekeepers and Peacemakers Association, the Papua New Guinea Volunteer Rifles Ex-Members Association and the Australian Water Transport Association. He serves on several national healthcare bodies and associations; and is the National President of the Scout Association of Australia.

12 Mrs Jean Pockett

Mrs Jean Pockett, a member of the War Widows Guild since 1970, is a long standing State Council member and is a past Vice President of the Guild, a position she held on four occasions. She has attended numerous national Conferences and been the Guild's delegate for the ex-Service Organisations. Mrs Pockett has served on the Executive Council and has been a member of the social committee.

She is a member of the Greenslopes Private Hospital Ex Service Organisation (ESO) Committee where she represents the whole of Queensland. She is very familiar with the campus at Greenslopes Private Hospital where she has volunteered as a hospital visitor for more than forty years. Her volunteer work was recognised in 2012 when she was presented with a 40 year Voluntary Service Certificate by the hospital executive. She was an inaugural board member of the Gallipoli Medical Research Foundation. She is also a member of the Queensland Cricketers' Club.



11



12

Board of Directors continued

13 Mr Tom Ryan

B Pharm, FACP, FAICD

Mr Tom Ryan formerly a Director and Chairman of Australian Pharmaceutical Healthcare Systems (APHS). Mr Ryan was a founding partner of the APHS Group. The APHS group provides pharmacy services within private hospitals, as well as providing oncology services to a variety of public and private hospitals and also providing an extensive service to aged care facilities for both prescription supply and clinical consultancies, and community pharmacy services. Mr Ryan owned and operated the pharmacy service at Greenslopes Private Hospital from 1995 until 2010.

14 Ms Toni Thornton

BA, GradDip, AFI

Ms Toni Thornton is a Non Executive Director of CS Energy, Devcorp and Habitat Early Learning as well as the Chair of the Audit Committee for CS Energy. Toni was an Executive Director with JBWere working in an investment advisory capacity to large Non-Profit groups, listed executives and Ultra High Net Wealth families. Toni is the former State Manager Queensland and Executive Director of Goldman Sachs JBWere.

Ms Thornton holds a Bachelor of Arts with a Politics major and minor in Economics and also holds a number of post graduate qualifications including Applied Finance and derivatives accreditations. She is a responsible executive of the ASX, has undertaken an Accelerated Executive Management program through the AGSM and has completed the Goldman Sachs JBWere non-profit leadership program. Toni has been with Goldman Sachs JBWere and JBWere for over 17 years in Investment Advisory roles in Sydney, a Strategic Management role in Melbourne working alongside the Managing Director –

PWM and in Brisbane where she was the State Manager for seven years. Ms Thornton previously sat on the board of the South Bank Corporation and the South Bank Corporation audit committee for 5 years.

15 Professor Ross Young

BSc(Hons), MSc, Dip, Clin Psyc, PhD, MAPS

Professor Ross Young was appointed Executive Dean, Faculty of Health QUT in January 2013 following seven years as Executive Director, Institute of Health and Biomedical Innovation (IHBI), QUT.

Professor Young is a Clinical Psychologist and his research interests lie in the integration of psychological and biological risk factors in mental illness. His research includes work in substance misuse, schizophrenia, anxiety disorders, mood disorders and more broadly in behavioural medicine. This includes work in pharmacogenomics and the development of personalised medicine via the use of gene chips. Professor Young has over 210 published book chapters and papers in genetic, medical, psychiatric and psychological journals.



13



14



15

Committees

GMRF Executive Committee

Members

Mr Liam Kelly (Chair)
 Prof Darrell Crawford
 Adjunct. Prof Tim Daniel
 Ms Miriam Dwyer
 Ms Suzanne Elliott
 Ms Frances McChlery
 Ms Carmel Monaghan
 Ms Jane O'Brien
 Ms Sharon Wood

GMRF Fundraising Subcommittee

Members

Ms Toni Thornton (Chair)
 Ass Prof David Colquhoun
 Mr Stephen Copplin

GMRF Finance and Audit Subcommittee

Members

Mr Stephen Copplin (Chair)
 Adjunct Prof. Tim Daniel
 Ms Toni Thornton
 Mr Tom Ryan
 Mr Liam Kelly
 Mr Karl Morris

GMRF Scientific Advisory Committee

Members

Prof Ross Young (Chair)
 Ass Prof David Colquhoun
 Prof Ken Donald
 Dr Michael Harrison
 Prof Gerald Holtmann

Veteran Health Strategic Oversight Committee

Members

Gerald Holtman (Chair)
 Ms Miriam Dwyer
 Dr Andrew Khoo
 Mr William O'Chee
 Ms Toni Thornton

GMRF Clinical Review Committee

Dr Glenda Powell, AM, MBBS, FRCP (Edin), FRACP, FAFRM
 Emeritus Consultant in Geriatric Medicine and Rehabilitation, Greenslopes Private Hospital; Emeritus at Princess Alexandra Hospital; Private Practice – Medico-Legal.

Ass Prof Christopher Strakosch, MD,FRACP
 Consultant Endocrinologist, Greenslopes Private Hospital; Associate Professor and Head, Discipline of Medicine. UQ, Greenslopes Campus.

Acknowledgements

We gratefully acknowledge the long term support and investment in our medical research by all of our supporters. We can continue to press on in our mission thanks to the generous support received over the past financial year.



RETURNED & SERVICES
LEAGUE OF AUSTRALIA
QUEENSLAND BRANCH



Discovery Partners

Our Discovery Partners come from a vast range of backgrounds but they are unified by a strong commitment to advancing research to restore lives. The Discovery Partner Honour Board is found in the heart of Greenslopes Private Hospital and acknowledges individuals and organisations that have chosen to become a part of our research team.

Corporate

Emeritus (\$1 million +)

RSL Queensland

Mastery (\$500,000 +)

Greenslopes Private Hospital

Ramsay Health Care

The University of Queensland Faculty of Health Sciences
– School of Medicine

Visionary (\$250,000 +)

Sullivan Nicolaides Pathology

Medinet

Innovator (\$50,000 +)

APHS

Baxter Healthcare

Device Technologies Australia

Johnson & Johnson Medical Pty Ltd

Medtronic Australasia Pty Ltd

Olympus Australia Pty Ltd

Philips Medical Systems

QML Pathology

Queensland University of Technology

Institute of Health & Biomedical Innovation (IHBI)

Queensland X-Ray

Roche Products Pty Ltd

Spotless Group Limited

Stryker Australia

Thynne + Macartney Lawyers

Community

Mastery (\$100,000 +)

Diggers Dozen Volunteers

War Widows Guild of Australia (QLD) Inc.

Visionary (\$50,000 +)

Kedron-Wavell Sub Branch RSL &

Kedron Wavell Services Club Inc.

Qld ex-Prisoner of War Association Inc.

Innovator (\$10,000 +)

Alma Williams & Friends

City of Brisbane Consistory No 1

A&AS Rite of Freemasonry

Coorparoo & Districts RSL Sub Branch

Gill's Old Bastards

Greenbank RSL Services Club Inc.

Greenbank RSL Sub Branch

Greenbank RSL Sub Branch Women's Auxiliary

Redlands RSL

Sherwood-Indooroopilly RSL Sub Branch

Sherwood Services Club Inc.

Stephens RSL Sub Branch

Walking on Sunshine

Wynnum RSL Services Memorial Club

Acknowledgements continued

Individual

Emeritus (\$100,000 +)

Mrs Norma Jean Bracken
John & Elaine Feddersen
Mark Kelly
Mr & Mrs John
& Wendy Thorsen
Blair & Joy Smith
Joanne Usher

Mastery (\$50,000 +)

The Barnett Family
Mr & Mrs Brett
& Zahra Godfrey
Pearl Logan, Lyn Unsworth
& The Logan Family
Foundation
Marjorie Trundle

Visionary (\$25,000 +)

Jeffrey Boyling
Mrs Betty Busing
Prof Darrell Crawford
Dr Chris & Dr Simone Layton
Mr & Mrs Bob
& Bernadette Ney
Dr Rowland Noakes
Miria, Mike, Rewiti & Tua Ross
Roger & Marjorie Trundle

Innovator (\$5,000 +)

Mr Rolf Albrecht
Dr L Barrett
The Broderick Family
Mr Leslie A Batros

Mr & Mrs Bernard & June Berry
Dr A Bofinger
Dr R Bach & Dr C Boothroyd
Mrs Mary & Mr Wally Boydell
Mrs Beris Broderick OAM
Mrs Margaret Brodie
Mr Malcolm Broomhead
Mr Vivian Byatt
Dr Lillian Cameron
Rick & Sue Chisholm
Bil Colthurst
Assoc Prof David Colquhoun
Mrs Joan Evelyn Court
Douglas & Helen Cowlshaw
Mr Douglas Cranstoun
Mr Peter Darmody
Mr & Mrs William
& Lynette Deacon
Dr Jeff Deslandes
Ms Helen du Frocq
Dr Stephen Fine
Mrs Jane Francis
Mr & Mrs D Fort
Mr Colin Garrett
Dr John Gibson
Mr Cyril Gilbert OAM
POW Changi
Mr David McDougall
POW Changi
Mr & Mrs Geoff
& Helen Glanville
Mr Cyril Golding
Prof Emeritus Richard D

Gordon AO
Mr Keith & Mrs Olive Gore
Mr G. M. Grant
Dr Trevor Gray
Bruce & Wendy Levien
Mr & Mrs Lloyd
& Sharon Grundy
Dr Ross Gurgo
Dr Bruce Hall
Mr Robin Harvey
Dr Steve & Julie Hearn
Mrs Patricia Hemsley
Dr Pia Iocavella
Mr & Mrs Robert
and Norma James
Dr Eileen Heyne
& Dr Imre Kalas
Dr R Kennedy
Dr N Kewal
Mr Alan Kinkade
Mr T Kinnane
Dr P Kortlucke
The Irving/Legerton Families
Keong Lim
Dr Ashim Majumdar
Mrs Freda Mangano
Dr Glenda McLaren
Mr James McNeil
Dr B Moore
Mr & Mrs Ken Naramura
Assoc Prof A Nicol
Assoc Prof D Nicol
Professor Andreas Obermair

Kevin & Miriam O'Shea
W G Patrick
Mrs J Pockett
Dr G Powell
Dr J Preston
Dr Kirsten & Dr Chris Price
Dr S Rahman
Dr J Reddrop
Mr Edward Rigden
Dr D Rosengren
Miria Ross
Roy Ryan
Henry & Judi Scheuber
Dr P Sharwood OAM RFD
Mrs Betty Smith
Ms Sheila B Smith
Dr Lynda Spelman
Mrs Anne Stanton
Assoc Prof Charles Steadman
Professor Michael Stowasser
Assoc Prof
Christopher Strakosch
Nr Nichalos (Pepper)
& Mrs Maria Taifalous
Mrs Jean Thompson
Mr & Mrs Brian
and Anne Thornton
Mrs Gwendoline C Trimble
Mrs Joye Trundle
Mrs Joanne Lesley Usher
Mr & Mrs Nicholas
& Eugenia Vallianos
Dr G Wagner

Dr Peter Waterhouse
Dr Noela Whitby AM
& Prof Michael Whitby
Dr Peter Whiting
Mrs Alma Williams
Mr & Mrs John
& Leone Wilson
Dr Glen & Mrs Susan Wood

Foundations, Trusts & Estates

Foundations

Paul Ramsay Foundation
Cory Charitable Foundation
Goldman Sachs JBWere Foundation
James N Kirby Foundation
State Trustees Australia Foundation
The Honda Foundation

Acknowledgements continued

Estates

Estate of Christina Ann Alexander
 Estate of Mr Victor John Bahr
 Mrs Norma June Bracken
 Estate of Mr Jeremiah Coffey
 Estate of
 Mrs Marjorie H Eastman
 Estate of Mrs Josie Clare Grinsell
 The Family of Dick
 & Elsie Hagerty
 Estate of
 Mrs Mary Lamond Hinkley
 Elizabeth Hughes
 Estate of Mr Mark Kelly
 Estate of Eugenie J MacLennan
 Mr G.D (Doug) Murray
 Estate of Shirelle Nahow
 Estate of Mrs Nancy Rauchle
 John and Joan Smith
 Estate of Mrs Joyce Smith
 Estate of Mrs Lucie Spatz
 Estate of
 Mrs Gwendoline C Trimble
 Estate of
 Mr Jeffery Allan Williamson

In Memoriam

Nulma Ball
 Keith and Marjorie Boyling
 Brian John Brandenburg
 Wilma Burnett
 Mrs Delia Helen Cameron
 Mrs Olga Clarke

Mrs Gert Francis
 Mr John Leslie Harrison
 Mr Lou Jurasko
 Henry James Elly Kinder (AE2, ex POW)
 (Buick) Ross Kinder (8th Division, ex POW)
 Cecil Gordon Lansdown
 Lynda Laughton
 Mrs Rhonda Linsdell
 The Miers Family
 Mrs Gemma Minto
 Lance and Eileen Ninnies
 Mr Jack Oliphant
 Kevin and Barbara Petersen
 Gilbert Stanley Rider
 David Shepherdson
 Col Shields
 Mr Leslie Francis Smith
 (ex P.O.W)
 Peter H Solomon
 Mr Michael Storah
 Darryl Sugars
 Wayne George Thomas
 Mr Paul Wilkinson
 Mrs May Young

Cyril Gilbert Testimonial Fund

The Cyril Gilbert Testimonial Fund was established to embrace the enduring spirit of one of Australia's great war heroes in our fight against cancer. The following donors have united to bring the fund to a level where it makes a truly impactful difference in cancer care:

Platinum 50K +

Greenslopes Private Hospital

Mr Paul Ramsay AO
 The QLD Ex Prisoner of War Association
 Mr and Mrs Blair and Joy Smith and Joanne Lesley Usher

Gold 20K +

Marjorie and Keith Boyling
 Mrs Colleen Makhecha
 RSL Queensland

Silver 10K +

Mrs Joanne Lesley Usher
 Sullivan Nicolaides Pathology
 Diggers Dozen –GPH
 Robert Peter Kemp
 Peta-Jane & Bruce Kemp

Bronze 5K +

Mr Cyril Gilbert OAM
 Associate Professor Andrew Nicol
 Mr Richard Lizzio
 Ms Carmel Monaghan
 Helen Parker & Betty Croft
 Premier Fire Pty Ltd
 Redlands RSL
 Mr Pat Welsh
 Dr Pretoria Bilinski
 Mrs Anne Maree Wright
 The Irving/Legerton Families

Acknowledgements continued

Volunteers

Gallipoli Medical Research Foundation (GMRF) values the incredible support given by the women and men who volunteer their time to support our research. We are ever grateful to the members of the Diggers Dozen volunteer group and to all Care Volunteers at Greenslopes Private Hospital. Your spirit and energy inspire us every day.

We are also particularly grateful for the volunteers who assisted GMRF with the planning and promotion of the Red Run 2017.

Clinical trial and research participants

GMRF would like to thank those who have directly contributed to medical research in the past 12 months through participation in a trials or studies.

Our PTSD and Veteran Mental Health Initiatives would simply not be possible without the involvement of veterans and their families who volunteered to participate in these studies.

The GMRF Clinical Trials Unit would also like to thank all patients for their time and participation in clinical trials across oncology, liver, and respiratory illnesses. It is thanks to these participants that we can conduct trials which will contribute to the general public having access to life-changing new treatments in the future.

1. The Diggers' Dozen volunteers at Greenslopes Private Hospital (GPH) have now raised over \$270,000 for GMRF's medical research



2. Diggers' Dozen volunteer, Lorraine O'Leary helps raise funds by collecting for a monthly raffle at GPH



3. Monica Rider (right) has been invaluable in sourcing sponsorships and prizes for GMRF events

Financial Highlights 2016–2017


Financially 2016/17 was another successful year for the Foundation. Total revenue grew to \$3.942M with the increase a result of higher revenue from clinical trials. We also saw growth in fundraising revenue thanks to our generous supporters.

Total expenditure was \$3.763M with 79.55% spent directly on research and clinical trial activities. Greenslopes Private Hospital continued to provide in-kind support in the form of rent, utilities and IT support which ensured our overheads remain very low. The clinical trials unit was able to generate sufficient surplus to cover these overheads to again allow 100% of all fundraising and donations to go directly towards our research. Cash reserves remain strong ensuring financial stability in the longer term.


"We are so grateful to the generous individuals, community groups and businesses that have made a significant contribution to our work in the past 12 months. We continue to proudly promise that 100% went directly to life-changing research and support programs."

Jane O'Brien, GMRF Operations Manager.

How we raised our income




How we used our total income




Covered by the income of our Clinical Trials Unit and the generous in-kind support of Greenslopes Private Hospital.

Expenditure Comparison 2015-2017



Income Comparison 2015-2017



Appendix – Publications per research unit

Liver Cancer Unit

Journal (peer reviewed)

Jayachandran A., Dhungel B., Steel JC. (2016) Epithelial-to-mesenchymal plasticity of cancer stem cells: therapeutic targets in Hepatocellular Carcinoma. *J Hematol. Oncol*, 9(1):74. doi: 10.1186/s13045-016-0307-9.

Tögel L, Nightingale R, Chueh AC, Jayachandran A, Tran H, Phesse T, Wu R, Sieber OM, Arango D, Dhillon AS, Dawson MA, Diez-Dacal B, Gahman TC, Filippakopoulos P, Shiao AK, Mariadason JM. (2016) Dual Targeting of Bromodomain and Extraterminal Domain Proteins, and WNT or MAPK Signaling, Inhibits c-MYC Expression and Proliferation of Colorectal Cancer Cells. *Mol Cancer Ther*. 2016;15(6):1217-26. doi: 10.1158/1535-7163.

Jayachandran A, Prithviraj P, Lo PH, Walkiewicz M, Anaka M, Woods BL, Tan B, Behren A, Cebon J, McKeown SJ. (2016) Identifying and targeting determinants of melanoma cellular invasion. *Oncotarget*. 2016 5;7(27):41186-41202. doi: 10.18632/oncotarget.9227.

Dhungel B., Jayachandran A., Layton CJ., Steel JC. (2017) Seek and Destroy: Targeted Adeno-associated Viruses for Gene Delivery to Hepatocellular Carcinoma. *Drug Del*. 24(1):289-299. doi: 10.1080/10717544.2016.1247926

Mir N.*, Jayachandran A.*, Dhungel B., Shrestha R., Steel JC. (2017) Epithelial-to-Mesenchymal Transition: a Mediator of Sorafenib Resistance in Advanced Hepatocellular Carcinoma. *Curr Cancer Drug Targets*. 2017;17(8):698-706. doi: 10.2174/1568009617666170427104356. *Equal contributing Authors.

Wang H, Zhang R, Bridle KR, Jayachandran A, Thomas JA, Zhang W, Yuan J, Xu ZP, Crawford DH, Liang X, Liu X, Roberts MS. (2017) Two-photon dual imaging platform for in vivo monitoring cellular oxidative stress in liver injury. *Sci Rep*. 7:45374. doi: 10.1038/srep45374.

Chüeh AC, Liew MS, Russell PA, Walkiewicz M, Jayachandran A, Starmans MHW, Boutros PC, Wright G, Barnett SA, Mariadason JM, John T. (2017) Promoter hypomethylation of NY-ESO-1, association with clinicopathological features and PD-L1 expression in non-small cell lung cancer. *Oncotarget*. 2017 23;8(43):74036-74048. doi: 10.18632/oncotarget.18198.

Published Abstracts:

Wood LV., Roberson BD., Agarwal P., Apolo AA., Stroncek D., Weiner LM., Morris JC., Steel JC., Terabe M., Lee M-J., Trepel J., Shim S., Berzofsky JA. (2016) Preliminary clinical activity and safety of an autologous AdHER2 dendritic cell vaccine in patients with advanced metastatic HER2+ solid tumors. *Cancer Immunol Res* 2016;4(11 Suppl):Abstract nr B001.

Toukam DK., Steel JC., Carwell C., Eldessouki I., Morris JC. (2017) A Cancer Stem Cell Vaccine Engineered to

Express Interleukin-15 and its Receptor Induces T Cell Proliferation. *Mol Ther*; 25 (5S1):158

Dhungel B., Jayachandran A, Shrestha R., Ramlogan-Steel C., Layton CJ., Steel JC. (2017) Evaluation of the Glypican-3 Promoter for Transcriptional Targeting of Hepatocellular Carcinoma. *Mol Ther*, 25 (5S1): 68

Conference Papers:

Jayachandran A, Wang H, Dhungel B., Steel JC. (2016) Targeting cancer stem cells in hepatocellular carcinoma. Colloquium of Metabolomics, Las Vegas, USA

Jayachandran A., Dhungel B., Shrestha R., Wang H., Huang I-T., Steel JC. (2017) Characterising and Combating the Immune-Modulatory Properties of Hepatocellular Carcinoma Derived Cancer Initiating Cells. IMMUNOTHERAPY@BRISBANE meeting, Brisbane, Australia.

Dhungel B., Jayachandran A., Layton CJ., Steel JC. (2017) Evaluation of tumor specific promoters for transcriptional targeting of Hepatocellular Carcinoma. Joint 10th Australasian Gene and Cell Therapy Society and Australasian Society for Stem Cell Research Scientific Meeting, Sydney.

Jayachandran A., Wang H., Dhungel B., Shrestha R., Huang I-T, Steel JC. (2017) Characterising Metabolic and Cellular Properties of Hepatocellular Carcinoma Derived Cancer Stem Cells. Joint 10th Australasian Gene and Cell Therapy Society and Australasian Society for Stem Cell Research Scientific Meeting, Sydney.

Liver Research Unit

Journal (peer reviewed)

Reiling J, Bridle KR, Schaap FG, Jaskowski L, Santrampurwala N, Britton LJ, Campbell CM, Jansen PLM, Damink SWMO, Crawford DHG, Dejong CHC, Fawcett J. The role of macrophages in the development of biliary injury in a lipopolysaccharide-aggravated hepatic ischaemia-reperfusion model. *Biochim Biophys Acta*. 2017 Jul 11. pii: S0925-4439(17)30226-0. doi: 10.1016/j.bbdis.2017.06.028.

ML Heritage, LA Jaskowski, KR Bridle, CM Campbell, D Briskey, LJ Britton, LM Fletcher, L Vitetta, VN Subramaniam, DHG Crawford (2017). Combination curcumin and vitamin E treatment attenuates diet-induced steatosis in Hfe-/- mice. *World Journal of Gastrointestinal Pathophysiology*, 8(2):67-76. doi: 10.4291/wjgp.v8.i2.67.

Haolu Wang, Run Zhang, Kim R. Bridle, Aparna Jayachandran, James A. Thomas, Wenzhu Zhang, Jingli Yuan, Zhi Ping Xu, Darrell H. G. Crawford, Xiaowen Liang, Xin Liu, Michael S. Roberts (2017). Two-photon dual imaging platform for in vivo monitoring cellular oxidative stress in liver injury. *Scientific Reports*, 7:45374. doi: 10.1038/srep45374.

J Reiling, KR Bridle, M Gijbels, FG Schaap, L Jaskowski, N Santrampurwala, LJ Britton, CM

Appendix continued

Campbell, SWM Olde Damink, DHG Crawford, CHC Dejong, J Fawcett (2017). Low-dose lipopolysaccharide causes biliary injury by blood biliary barrier impairment in a rat hepatic ischemia/reperfusion model. *Liver Transplantation*, 2017 Feb;23(2):194-206.

McLeay SC, Harvey WM, Romaniuk MN, Crawford DH, Colquhoun DM, Young RM, Dwyer M, Gibson JM, O'Sullivan RA, Cooksley G, Strakosch CR, Thomson RM, Voisey J, Lawford BR. Physical comorbidities of post-traumatic stress disorder in Australian Vietnam War veterans. *Med J Aust*. 2017 Apr 3;206(6):251-257.

Wood MJ, Crawford DH, Wockner LF, Powell LW, Ramm GA. Serum ferritin concentration predicts hepatic fibrosis better than hepatic iron concentration in human HFE-Haemochromatosis. *Liver Int*. 2017 Feb 23. doi: 10.1111/liv.13395. [Epub ahead of print]

Wang H, Liang X, Gravot G, Thorling CA, Crawford DH, Xu ZP, Liu X, Roberts MS. Visualizing liver anatomy, physiology and pharmacology using multiphoton microscopy. *J Biophotonics*. 2017 Jan;10(1):46-60. doi: 10.1002/jbio.201600083. Epub 2016 Jun 17.

Alqahtani S, Ozaras R, Isakov V, Wyles D, Ferenci P, Feld JJ, Calinas F, Gschwantler M, Gane E, Crawford D, Jacobson IM, Dumas EO, King M, Sulkowski M. Time to viral suppression is not related to achievement of SVR12 in HCV GT1-infected patients treated with ombitasvir/paritaprevir/ritonavir and dasabuvir with or without ribavirin. *J Viral Hepat*. 2017 Apr;24(4):280-286. doi: 10.1111/jvh.12641. Epub 2016 Dec 9.

Britton LJ, Subramaniam VN, Crawford DHG. Iron and non-alcoholic fatty liver disease. *World J Gastroenterol*. 2016 Sep 28;22(36):8112-22. doi: 10.3748/wjg.v22.i36.8112. Review.

Published abstract

J Reiling, A Simpson, KR Bridle, D Lockwood, N Santrampurwala, L Britton, CHC Dejong, DHG Crawford, J Fawcett, The application of normothermic machine perfusion to bench test human donor livers. *Journal of Gastroenterology and Hepatology* (2016) 31 (suppl. 2).

PM Hlaing, KR Bridle, LA Jaskowski, WM Harvey, DHG Crawford. Liver disease in Vietnam veterans: a comparison of veterans with and without PTSD. *Journal of Gastroenterology and Hepatology* 2016; 31 (Suppl. 2): 104.

J Reiling, KR Bridle, N Santrampurwala, LJ Britton, C Campbell, DHG Crawford, CHC Dejong, J Fawcett, Lipopolysaccharides increase bile toxicity and induce severe biliary injury in an LPS enhanced ischaemia-reperfusion model. 2016, HPB;18:e126-e127.

Veteran Mental Health Initiative

Journal (Peer reviewed)

2017 Kerr K, Romaniuk M, McLeay S, Khoo A, Dent M and M Boschen. Total and permanent incapacitation, unemployment and PTSD severity is associated with increased risk of attempted suicide in Australian veterans. *Australian and NZ Journal of Psychiatry*. In press.

Commissioned Reports

Romaniuk, M., Evans, J., & Kidd, C. (2017). Evaluation of the 'Post War: Survive to Thrive Program' for Ex-Service Personnel. Commissioned by Returned and Services League of Australia.

Romaniuk, M., & Evans, J. (2017). Evaluation of the 2016 Mates4Mates Equine Therapy Program. Commissioned by Returned and Services League of Australia.

Published Abstracts (accepted presentations)

Romaniuk, M. (2016, September). From Soldier to Civilian: Fragmented Culture and Identity of Afghanistan and Iraq Veterans - the Relationship with PTSD,

Anger and Implications for Treatment. 19th Australasian Conference on Traumatic Stress, Gold Coast Australia.

Romaniuk, M. From Soldier to Civilian: Culture clashes observed by mental health clinicians and the impact on the reintegration process. *Journal of Military and Veterans' Health*, 2016; 24(4):25

Kerr K, Romaniuk M, McLeay S, Khoo A, Dent M & Boshen M. Re-experiencing trauma as a predictor of suicide risk among Vietnam veterans with posttraumatic stress disorder. *Journal of Military and Veterans' Health*, 2016; 24(4):67

Romaniuk, M. From Service to Civilian Life: Emerging Patterns from an Australian Investigation Examining Common Factors Among Those Who Transition Well in the Context of Cultural Reintegration and Psychological Adjustment. Accepted for presentation to the 8th annual conference of the Canadian

Institute for Military and Veteran Health Research (CIMVHR), in partnership with the Invictus Games, September 25 - 27, 2017 in Toronto, Canada.

Romaniuk, M., Evans, J., Kidd, C., Gilmour, J. Evaluation of the Psychological Outcomes of

Appendix continued

an Equine Therapy Program for Current and Former Australian

Armed Forces with Mental Health Difficulties. Accepted for presentation to the 8th annual conference of the Canadian Institute for Military and

Veteran Health Research (CIMVHR), in partnership with the Invictus Games, September 25 - 27, 2017 in Toronto, Canada.

Kidd, C., Romaniuk, M., Bruenig, D. Dimensions of Resilience among Australian Vietnam War Veterans: Exploratory Factor Analysis of the Connor-Davidson

Resilience Scale and Relationship with Psychopathology. Accepted to Australasian Military Medicine Association Conference 2017.

Evans, J., Romaniuk M. Evaluation of the Post War: Survive to Thrive Online Program for Ex-service Personnel. Accepted to Australasian Military Medicine Association Conference 2017.

Theal R, Tay VXP and IJ Hickman. Dietary intake and associations with cardiometabolic health in Australian Vietnam veterans with and without post-traumatic stress disorder (PTSD). Accepted to Australasian Military Medicine Association Conference 2017.

Romaniuk, M. Factors that Contribute to Effective Transition from the ADF in the Context of Cultural Reintegration and Psychological Adjustment. Invited speaker at the International PTS17 Forum, September 2017.

Evans, J. Online programs to support recovery. Invited speaker at the International PTS17 Forum, September 2017.

PTSD Initiative

Journal (peer reviewed)

Bruenig D, Lurie J, Morris CP, Harvey W, Lawford B, Young RM, et al. A Case-Control Study and Meta-Analysis Reveal BDNF Val66Met Is a Possible Risk Factor for PTSD. *Neural plasticity*. 2016;2016:6979435.

McLeay SC, Harvey WM, Romaniuk MN, Crawford DH, Colquhoun DM, Young RM, et al. Physical comorbidities of post-traumatic stress disorder in Australian Vietnam War veterans. *Med J Aust*. 2017;206:251-7.

Bruenig D, Mehta D, Morris CP, Harvey W, Lawford B, Young RM, et al. Genetic and serum biomarker evidence for a relationship between TNFalpha and PTSD in Vietnam war combat veterans. *Comprehensive psychiatry*. 2017;74:125-33.

Bruenig D, Morris CP, Mehta D, Harvey W, Lawford B, Young RM, et al. Nitric oxide pathway genes (NOS1AP and NOS1) are involved in PTSD severity, depression, anxiety, stress and resilience. *Gene*. 2017;625:42-8.

Mehta D, Bruenig D, Carrillo-Roa T, Lawford B, Harvey W, Morris CP, et al. Genomewide DNA methylation analysis in combat veterans reveals a novel locus for PTSD. *Acta psychiatrica Scandinavica*. 2017;136:493-505.

Akosile W, Young R, Lawford B, Voisey J, Colquhoun D. PTSD symptoms associated with myocardial infarction: practical clinical implications. *Australasian psychiatry : bulletin of Royal Australian and New Zealand College of Psychiatrists*. 2017;1039856217734738.

Published abstract/accepted presentations

2016 Gleeson S, Law D, Lowrie F, Theal R, McLeay S and R O'Sullivan. The use of actigraphy to assess sleep patterns in Vietnam veteran with and without post-traumatic stress disorder. *Journal of Sleep Research, Special Issue: Sleep DownUnder 2016 'Connections Abstracts*, 2016; 25 (Suppl. S2):41

2016 Hlaing PM, Bridle KR, Jaskowski LA, Harvery WM and DHG Crawford. Liver disease in Vietnam veterans: A comparison of veterans with and without PTSD. *Journal of Gastroenterology and Hepatology*, 2016; 31 (Suppl. 2):104

2016 Romaniuk M. The relationship between PTSD symptom severity and cortical white matter integrity among trauma exposed war veterans utilising diffusion tensor imaging (DTI). *International Society for Traumatic Stress Studies, 32nd Annual Meeting Poster Abstract Book*: 64-65

2016 Colquhoun D, Crawford D, Wright J and S Mcleay. Post-traumatic stress disorder (PTSD and coronary artery cardiac (CAC) score. *Heart, Lung and Circulation* 2016; 25 (Suppl. 2):S245

2016 Bruenig D, Morris C, Young RM & Voisey J. NOS1AP is associated with PTSD severity, depression, anxiety and stress. *Australasian Conference on Traumatic Stress* 2016.

2016 Romaniuk M. Comparing microstructural connectivity of cortical white matter tracts

Appendix continued

in war veterans with and without PTSD using tractography. Australasian Conference on Traumatic Stress 2016.

2017 Mehta D. Genome-wide DNA methylation analysis in combat veterans reveals a novel locus for PTSD. *Biological Psychiatry* 2017; 81-10 (Suppl.)

NTM Research Unit

Journal (peer reviewed)

2017 Samuel Halstrom, Rachel Thomson, Hayley Goullee, Svetlana Baltic, Richard Allcock, Suzanna E L Temple, Patricia Price, Susceptibility to non-tuberculous mycobacterial disease is influenced by rs151811 in IL-10. *Human Immunology* 2017;78(4):391-3

2017 Rachel Thomson, Ellen Donnan, Tom Konstantinos, Notification of Nontuberculous Mycobacteria: an Australian perspective. *Annals of the American Thoracic Society* 2017;14(3):318-323

2017 McLeay SC, Harvey WM, Romaniuk MN, Crawford DH, Colquhoun DM, Young RM, Dwyer M, Gibson JM, O'Sullivan RA, Cooksley G, Strakosch CR, Thomson RM, Voisey J, Lawford BR. Physical comorbidities of post-traumatic stress disorder in Australian Vietnam War veterans. *Med J Aust* 2017; 206(6):251-57

2017 Patricia Price, Samuel Halstrom, Catherine Cherry, Michael Black, Rachel Thomson, Hayley Goullee, Svetlana Baltic, Richard Allcock, Suzanna Temple. A haplotype spanning P2X7R, P2X4R and CAMKK2 may mark susceptibility to pulmonary non-tuberculous mycobacterial disease. *Immunogenetics* 2017;69(5):287-293

2016 Josephine M Bryant, Dorothy M Grogono, Daniela Rodriguez-Rincon, Isobel Everall, Karen P Brown, Pablo Moreno, Deepshikha Verma, Emily Hill, Judith Drijkoningen, Peter Gilligan, Charles R Esther, Peadar G Noone, Olivia Giddings, Scott C. Bell, Rachel Thomson, Claire E. Wainwright, Chris Coulter, Sushil Pandey, Michelle E Wood, Rebecca E Stockwell, Kay A Ramsay, Laura J Sherrard, Timothy J Kidd, Nassib Jabbour, Graham R Johnson, Luke D Knibbs, Lidia Morawska, Peter D Sly, Andrew Jones, Diana Bilton, Ian Laurenson, Michael Ruddy, Stephen Bourke, Ian CJW Bowler, Stephen J Chapman, Andrew Clayton, Mairi Cullen, Thomas Daniels, Owen Dempsey, Miles Denton, Maya Desai, Richard Drew, Frank Edenborough, Jason Evans, Patricia Fenton, Jonathan Folb, Helen Humphrey, Barbara Isalska, Søren Jensen-Fangel, Bodil Jönsson, Andrew M. Jones, Terese L

Katzenstein, Troels Lillebaek, Gordon MacGregor, Sarah Mayell, Michael Millar, Deborah Modha, Edward F Nash, Christopher O'Brien, Deirdre O'Brien, Chandra Ohri, Caroline S Pao, Daniel Peckham, Felicity Perrin, Audrey Perry, Tania Pressler, Laura Prtak, Tavs Qvist, Ali Robb, Helen Rodgers, Kirsten Schaffer, Nadia Shafi, Jakko van Ingen, Martin Walshaw, Danie Watson, Noreen West, Joanna Whitehouse, Charles S Haworth, Simon R Harris, Diane Ordway, Julian Parkhill & R. Andres Floto. Population-level genomics identifies the emergence and global spread of a human transmissible multidrug-resistant nontuberculous mycobacterium. *Science* 2016;354:751

2016 Gianni P. Scoleri, Jocelyn M. Choo, Lex E.X. Leong, Thomas R. Goddard, Lisa Shephard, Lucy D. Burr, Ivan Bastian, Rachel M. Thomson, Geraint B. Rogers. Culture-independent detection of nontuberculous mycobacteria in clinical respiratory samples. *Journal of Clinical Microbiology* 2016; 54(9): 2395-98

2017 Book Chapter in CLINICAL HANDBOOK OF NONTUBERCULOUS MYCOBACTERIA, SECTION II: CLINICAL ASPECTS 5. Prevention and control

2017 Book Chapter in VICTORIAN TUBERCULOSIS HANDBOOK. Chapter 10: NTM infections

Published Abstracts

2017 Tim Baird, Geoff Eather, Robyn Carter, Rachel Thomson. Mycobacterium shimoidei- a rare but increasingly recognised pulmonary pathogen. *Am J Resp Crit Care Med* 2017;195:A5071

2017 Visser S, Allan, H, Burr L, Chang A, Holmes-Liew C-L, Hunter C, Jackson D, King P, Maguire G, Middleton P, Smith D, Thomson R, Waterer GW, Wong C, Morgan L.

2017 The Australasian Bronchiectasis Registry- early steps in mapping the impact of bronchiectasis in Australia and New Zealand. *Am J Resp Crit Care Med* 2017; 195:A4723

2017 Choo J, Abell G, Burr L, Thomson R, Morgan L, Grant G, Gordon D, Taylor S, Leong L, Rogers G. The impact of long-term erythromycin therapy on the oropharyngeal microbiota and associated resistome. World Bronchiectasis Conference, Milan 2017 (to be published in the European Respiratory Journal)

Appendix continued

Ophthalmology Unit

Journal (peer reviewed)

Kaway CS, Adams MKM, Jenkins KS, Layton CJ (2017). A novel ABCA4 mutation associated with late-onset stargardt disease phenotype: a hypomorphic allele. *Case Rep Ophthalmol* 8 (1) 180-184

Jenkins KS, Layton CJ. (2017) External Ophthalmomyiasis caused by *Oestrus Ovis*. *Clin Exp Ophthalmology* (in press)

Jenkins KS, Layton CJ (2017) Why are cost analysis methods important in clinical ophthalmology? An illustrative analysis of orbital fracture triage. *Ophthalmic Epidemiology* (under review)

Layton CJ, Kawai CS, de Moraes G, Jenkins K, Goh AY (2017). Effects of erythropoietin on glucose induced exacerbation of hypoxic damage in cultured photoreceptor-like cells. *Invest Ophthalmol Vis Sci* 57 (12) 3228-3228

Jenkins KS, Layton CJ (2017) Systematic Assessment of Clinical Methods to Diagnose and Monitor Diabetic Retinal Neuropathy. *Acta Ophthalmologica* (under review)

Goh AY, Jayachandran A, Ramlogan-Steel C, Steel JC, Layton CJ (2017). Genetic evidence for the role of UV light in the pathogenesis of uveal melanoma. *Clin Exp Ophthalmol* (under review)

Goh AY, Jayachandran A, Ramlogan-Steel C, Steel JC, Layton CJ (2017). UV and short wavelength light in the pathogenesis of uveal melanoma. *Clin Exp Ophthalmol* (under review)

Jenkins KS, Rowan A, Layton CJ. (2016) An eye for art? The challenge of ophthalmic body modification. *Clin Exp Ophthalmol* 44 (8) 741-741

Conference Paper (peer reviewed)

Adams M, Kawai C, de Moraes G, Jenkins KS, Layton CJ. (2017) Novel ABCA4 mutation associated with late-onset Stargardt's disease phenotype: a hypomorphic allele?. *ARVO ASIA, Brisbane, Australia*

Dhungel B, Andrezewski S, Jayachandran A, Steel J, Layton CJ (2017) Optimization of Adeno-Associated Viruses for Gene Therapy of Uveal melanoma *ARVO ASIA, Brisbane, Australia*

Jenkins KS, Layton CJ. (2017) A Cost-Effectiveness Analysis of LOGMar-visual acuity-driven protocol for referral of orbital fractures not requiring surgery to ophthalmic follow-up. *ARVO ASIA, Brisbane, Australia*

Murali A., Ramlogan-Steel C., Andrzejewski S., Dhungel B., Steel J., Layton C. (2017) The 8-fold quadrant dissection method for ex vivo human interventional retinal experimentation. *European Association for Vision and Eye Research 2017 Congress. Nice, France*

Layton CJ*, Dhungel B*, Andrzejewski S, Jayachandran A, Ramlogan-Steel C, Steel J (2017) Gene therapy targeting of choroidal disease and AAV transcytosis through the outer blood retina barrier epithelium. *European Association for Vision and Eye Research 2017 Congress. Nice, France*

Ramlogan-Steel C*, Goh A*, Jayachandran A, Steel J, Layton CJ. (2017) Genetic Evidence of the role of UV light in the pathogenesis of UV melanoma. *European Association for Vision and Eye Research 2017 Congress. Nice, France*

How you can help

All donations of \$2 or more are tax deductible – thank you.

Donate

If you would like to donate to our work please contact the Foundation Office using the details listed on this page. Donations can be made by cash, cheque, or credit card.

You can also donate online via our website www.gallipoliresearch.com.au.

Become a Regular Giver

Regular donations are essential for the Foundation to plan ahead for future initiatives, secure in the knowledge of regular financial support. If you would like to donate to our work please contact the Foundation Office using the details listed on this page.

GMRF Regular Givers receive an itemised tax receipt for all donations each year, allowing you to process your tax return more easily.

Become a Discovery Partner

GMRF's research planning decisions must be considered in multiple year time frames, even though most of our funding is only sourced on an annual basis. Our Discovery Partners are committed supporters who confirm their intention to support us into the future, thereby giving us the security to reach for even bigger goals in our quest for new treatments and breakthroughs.

If you would like information on the Discovery Partner program, please contact Anna Coles (GMRF Philanthropy Manager) on 07 3394 7105 or ColesAnna@ramsayhealth.com.au.

Memorial Gifts

Memorial donations can be made to the GMRF in lieu of floral tributes. Memorial gift envelopes are available from the Foundation Office or can be requested via your funeral director.

Community Fundraising

GMRF relies on the amazing efforts of many individuals and community groups to raise funds in their local community. If you or your community group would be interested in finding out more about how to do this, please contact Maria Noonan (GMRF Communications Coordinator) on 07 3394 6776 or NoonanMaria@ramsayhealth.com.au.

Bequests

Leaving a bequest in your Will is one of the most significant ways you can assist our work and leave a lasting legacy for future generations. After considering family and friends, you might consider making a provision in your Will to assist GMRF.

If you would like a copy of our Information Pack to help you in planning your Bequest, please contact Anna Coles (GMRF Philanthropy Manager) on 07 3394 7105 or ColesAnna@ramsayhealth.com.au.

Add your name to the GMRF Discovery Partners honour board

We are proud to display donations of over \$5,000 on the GMRF Discovery Partners honour board, located in the heart of Greenslopes Private Hospital. We update the honour board once a year, in time for Remembrance Day. If you would like to make a donation and add your name or the name of a loved one to the board, please contact Anna Coles (GMRF Philanthropy Manager) on 07 3394 7105 or ColesAnna@ramsayhealth.com.au.

Our promise to you

We are fortunate to receive a great deal of in-kind support from Greenslopes Private Hospital which, in combination with the income we derive from our Clinical Trials Unit, pays for the administration costs of our Foundation. Therefore, 100% of the money you give us goes directly to medical research.

Other ways to help

Volunteering



The Diggers Dozen volunteers, based at Greenslopes Private Hospital, are always on the lookout for new volunteers. If you can help, please contact President Joan Harris on (07) 3394 7026.

Stay in touch

Hear the latest research news and spread the word about the important work happening at GMRF.

Tribute is the research newsletter of GMRF, produced twice a year. Contact us by email or telephone to receive your personal copy.

You can also follow us on:

 www.facebook.com/GallipoliResearch
 @GMRF

Foundation Office contact details:

Gallipoli Medical Research Foundation
 Greenslopes Private Hospital
 Newdegate Street, GREENSLOPES QLD 4120
 T: (07) 3394 7284
 Fax: (07) 3394 7767
 E: enquiries.gmrf@ramsayhealth.com.au
 W: www.gallipoliresearch.com.au
 ABN 42 077 750 693

Honouring the legacy of Simpson and his donkey


The Gallipoli Medical Research Foundation logo includes a representation of Simpson and his donkey, a well known and much loved icon that epitomises the sacrifice made by our brave service personnel at Gallipoli and in many conflicts since that tragic but heroic chapter in our history. The commitment, dedication and selflessness that enabled Simpson to go out, time and again, to rescue his wounded comrades encourages us to strive towards excellence in medical research so that others can benefit in this generation and generations to come.

John Simpson Kirkpatrick was born and lived until age sixteen in South Shields, Tyneside, UK. One of a family of seven including his father, Robert, a merchant navy seaman and Sarah, his mother who also worked as a domestic housekeeper, John's young life was difficult. Food was scarce, the neighbourhood was poor and the family moved frequently. His father passed away, five years after he left the navy because of injury. John was 17. He had left school at 12 to take up work as a "milk-float boy". He worked with a dappled grey pony who became his close friend; others remarking on the fact that John talked to the pony like he would another human being.

When his father died, John went to sea and on his second ship he came to Australia. He worked here for four years, on coastal shipping vessels and he tried cane cutting and horse-mounted stock work in Northern Queensland. These latter jobs each lasted only a matter of days; John found the heat and humidity intolerable. When war broke out in 1914, he was one of the first to enlist in Perth where he joined the 3 Australian Field Ambulance as a stretcher bearer.

The legend of Simpson's deeds at Gallipoli was forged in only 24 days at Anzac Cove. It is believed that he rescued and retrieved more than 300 casualties, sometimes as many as 20 in one day, many under conditions of mortal risk to himself. On 19 May 1915, while making his fourth rescue of the day under heavy fire, he was killed instantly by machine gun fire at a point known as Bloody Angel in Shrapnel Gully. His donkey, "Duffy" still carrying the wounded soldier returned alone to the Advanced Dressing Station of 3 Field Ambulance.

Acknowledgement: Professor John Pearn AO,
Professor of Paediatrics and Child Health –
University of Queensland and Major General (Rtd.)



Thank you!

The research conducted by the Gallipoli Medical Research Foundation (GMRF) in the past year has only been possible as a result of the generosity of our donors – thank you.

We receive no Government funding and, therefore, continue to rely completely on your support. Every gift, however big or small, will make a difference and help save lives.

Our promise to you:

We are fortunate to receive a great deal of in-kind support from Greenslopes Private Hospital which, in combination with the income generated from our Clinical Trials Unit, pays for the administration costs of our Foundation. What this means is 100% of the money you give us goes directly to medical research.



Gallipoli Medical Research Foundation
Greenslopes Private Hospital
Newdegate Street
GREENSLOPES QLD 4120

T: (07) 3394 7284 Fax: (07) 3394 7767
E: enquiries.gmrf@ramsayhealth.com.au
W: www.gallipoliresearch.com.au
ABN 42 077 750 693